Clinical Trial

PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 8, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients hospitalized for acute decompensation of CHF are usually complicated by worsening renal function (WRF) which leads to diuretic resistance and inadequate decongestion as well as poor prognosis. WRF has been attributed to a reflex renal vasoconstriction elicited by intravascular volume depletion during brisk diuresis. The investigators hypothesize that CHF patients with hepatic dysfunction are more prone to WRF due to poor albumin production. This sub-group of CHF patients may benefit more (increased diuretic efficacy and protected against worsening renal function) by the use of IV loop diuretics in combination with an intravascular volume expander such as IV Human Albumin.
Trial Details
NCT Number NCT06630923
Lead Sponsor Democritus University of Thrace
Conditions Diuretics Drug Reactions, Heart Failure; With Decompensation, Albumin; Double
Enrollment 250 participants
Start Date 2023-01-14
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-12-11 (estimated)
Updated on ClinicalTrials.gov 2024-10-08